Convatec secures regulatory approval for ConvaMatrix™ in UK and Europe, supporting more patients with pioneering skin substitute technology

London, UK, 22 September 2025 – Convatec, a leader in medical products and technologies focused on solutions for chronic conditions, has received EU and UK regulatory approval for ConvaMatrix™*, a unique porcine placenta-derived medical device designed to support the body’s natural healing response for hard to heal wounds.

 

ConvaMatrix^TM is an innovative, single use, skin substitute wound dressing. It has significant potential for the management of hard to heal wounds such as venous leg ulcers and diabetic foot ulcers and can be used in hospitals, outpatient clinics, long-term care facilities, and home care by healthcare professionals. The porcine derived extracellular collagen matrix wound dressing is intended to cover, protect, and provide a moist wound environment to support the body’s natural healing process.

 

The approval of this technology enables Convatec to launch ConvaMatrix™ in Europe from 2026, and will bring significant health benefits¹ to patients and healthcare professionals across the continent.

 

Tanja Dormels, President & Chief Operating Officer, Advanced Wound Care, Convatec, said: “ConvaMatrix™ is an excellent product and its approval means that it will soon be used to enhance the quality of life for people living with diabetic foot ulcers and venous leg ulcers across Europe. This milestone represents the fourth new wound care technology Convatec has secured approval for over the last twelve months, demonstrating our commitment to pioneering, innovative solutions to support patients and healthcare professionals.”

 

ConvaMatrix^TM is the latest innovative Convatec wound care platform that has received regulatory approval in Europe and UK over the last twelve months, following quickly after ConvaFoam^TM, ConvaNiox^TM and Aquacel^TM ConvaFiber^TM. The roll out of these products will scale up in 2026 as Convatec continues to provide innovative solutions to treat hard to heal wounds and improve care for the lives of millions of people.

 

Contacts

Media: mediarelations@convatec.com

Analysts & investors: ir@convatec.com

 

Notes to editors

The EU certification (CE mark) and UK certification (UKCA mark) confirms that ConvaMatrix™ meets the rigorous safety and performance requirements of the Medical Devices Regulation (EU) 2017/745 and UK Medical Device Regulation 2002 respectively.

 

*About ConvaMatrix™

Convatec’s ConvaMatrix^TM was originally certified as InnovaMatrix^® in the United States. The product was cleared by the US Food and Drug Administration (FDA) and is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunnelled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second degree burns and skin tears) and draining wounds.

 

Patients and HCPs have experienced first-hand the positive, sometimes limb-saving, impact that InnovaMatrix^® products have on chronic wounds¹. 

Convatec remains committed to evidence-based medicine to improve outcomes for patients and choice for HCPs. Our randomised controlled trials (RCTs) are on track to report in 2026. This will complement our published real-world evidence (RWE), including RWE published in December 2024¹. Further RWE will be published before the end of the year.

 

References

1. Fife C, LeBoutillier B, Taylor C, Marcinek BT. Real-World Use and Outcomes of Hard-To-Heal Wounds Managed With Porcine Placental Extracellular Matrix. Cureus. 2024 Dec 23;16(12):e76262. doi: 10.7759/cureus.76262. PMID: 39720774; PMCID: PMC11668260 https://pubmed.ncbi.nlm.nih.gov/39720774/

 

About Convatec 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com